Agoracom Blog Home

Posts Tagged ‘CBD’

Tetra Bio-Pharma Expands Focus of Commercialization Activities into the Lucrative Veterinary Market $TPB.ca

Posted by AGORACOM-JC at 8:27 AM on Wednesday, June 28th, 2017

Tbp large

  • Commercializing novel cannabinoid based formulations for the treatment of pet conditions
  • Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities

OTTAWA, ONTARIO–(June 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment of pet conditions.

Over the last year, Tetra demonstrated its leadership in the development of human prescription cannabinoid drugs and will use the same strategy to become a leader in the field of veterinary cannabinoid drug products. Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities. In fact, Tetra is well suited to tackle the veterinary drug market since the ACMPR was created to allow human patient’s access to medical marijuana and does not provide any measures to allow testing of cannabis or cannabis derived products in pets.

According to a USA Federal Trade Commission May 2015 report, in 2014, Americans spent approximately $58 billion on their pets, including medications. This number more than doubled since 2001. This market is expected to enjoy excellent growth over the next decade as new therapies provide better and more tolerable treatment for pets. According to Andre Rancourt, CEO of Tetra Bio-Pharma, “After carefully studying the veterinary pet market and potential partnerships, the company decided to expand its development activities in order to tap into this lucrative market. In addition, Tetra is very fortunate to have Dr. Chamberland who has considerable experience navigating the regulatory affairs in the veterinary industry.”

Tetra had announced the successful completion of several corporate milestones associated with the development of its prescription drug products. These announcements lead to discussions with veterinary specialists who expressed the need for novel cannabinoid therapies for pets.

Tetra will create a Veterinary Advisory board consisting of veterinary specialists in the fields of ophthalmology, oncology and pain. This board of veterinary experts will help guide the development to ensure that the products target unmet veterinary needs for domestic animals. Tetra will use the veterinary drug development program to expand its potential revenues from the sales of a drug product in both the human and pet drug markets. The corporation will also establish partnerships with pharmaceutical companies specialized in the sale and distribution of veterinary products.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Announces UNB Cannabis Health Research Chair $TBP.ca

Posted by AGORACOM-JC at 9:26 AM on Tuesday, June 13th, 2017

Tbp large

  • Tetra Bio-Pharma Inc. and The New Brunswick Health Research Foundation are investing a combined $1 million,
  • $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB)

OTTAWA, ONTARIO–(June 13, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) and The New Brunswick Health Research Foundation are investing a combined $1 million, $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB).

The chair will focus on the study of biochemistry, medicinal use and pharmacology of cannabis. This research will expand UNB’s commitment to research and innovation in the field of natural product and biomedical, health and life sciences – adding to its reputation as a leader in natural products’ research.

“The Cannabis Health Research Chair is a key example of the university’s commitment to discovery,” says Dr. David Burns, Vice-President (Research), UNB. “We believe in the power of research to advance innovation within New Brunswick. With 75 per cent of the province’s public funded research taking place at UNB, we’re thrilled to play a central role.”

Potential research areas for the chair include the analysis of existing cannabis literature, in order to understand inconsistencies and identify needs for future research; the biochemistry and medicinal chemistry analyses of cannabis; and preclinical pharmacology studies.

“Health research is instrumental in helping us find better ways to provide patient care in our province,” says Health Minister Victor Boudreau. “This new Cannabis Research Chair will certainly provide crucial and innovative information on the use of cannabis as a medical treatment.”

“We are honoured to invest with the New Brunswick Health Foundation in establishing a research chair at the University of New Brunswick as Tetra positions itself as a global leader in pharmaceutical cannabis,” said Andre Rancourt, CEO of Tetra Bio-Pharma.

The recruitment and nomination process will be conducted at the University of New Brunswick for a tenured track faculty member. Funding for the chair is expected to start in the 2017-18 fiscal year.

Dr. Guy Chamberland, Chief Scientific Officer of Tetra Bio-Pharma added: “Over the past few years, the province of New Brunswick has positioned itself on the forefront as global leaders in the development of cannabis products for health care. The Tetra team has partnered with the New Brunswick Health Research Foundation to help bring innovative cannabis-based therapies to patients. We have no doubt that when established, the work of this new chair will contribute significantly to this network by providing crucial information on the safety toward implementing new cannabis based products to practitioners working to help improve the quality of life for patients specifically living with chronic pain.”

This research will expand the university’s capacity to train, mentor and prepare undergraduate and graduate students to work effectively in botanical product research.

“The present Health Research Chair, the second one announced within a month, clearly signifies New Brunswick’s intention to be at the forefront of cannabis research. This competitive Chair will further develop the science toward implementing proven and safe innovative cannabis-based therapies for the chronic treatment of various disorders (pain, PTSD, etc.),” says Dr. Bruno Battistini, President, CEO and Scientific Director of the New Brunswick Health Research Foundation.

“New Brunswick, with such entities as UNB, the NB Research and Productivity Council, and Tetra Bio-Pharma as the private sector partner, create a unique association, leveraging scientific and innovation expertise that will strongly address the clinical challenges introduced by the legalization and regulation of this natural product.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
www.tetrabiopharma.com

 

Marijuana Company of America, Inc Announces the Launch of New Website $MCOA.us

Posted by AGORACOM-JC at 8:52 AM on Thursday, May 18th, 2017

15233 mcoa

  • Launched its new corporate website; www.marijuanacompanyofamerica.com.
  • Provides shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans

BONSALL, CA–(May 18, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or “the Company”) (OTC PINK: MCOA), an innovative cannabis and industrial hemp corporation, is pleased to announce the launch of its new corporate website; www.marijuanacompanyofamerica.com.

The new website will provide our shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans, this new site will be the central hub for information about MCOA and the rapidly emerging cannabis and hemp industry.

Since starting the process to become fully reporting and uplisting to a higher financial exchange, the OTCQB, the Company has been engaging with institutional investors and analyzing meaningful M&A opportunities in the cannabis and industrial hemp marketplaces. This new site will be a useful tool in providing investors with updates on these developments.

MCOA recently engaged Hill and DraKoln Media (“H&D”) to develop the new website and provide marketing and brand management support. MCOA looks forward to capitalizing on H&D’s ability to communicate clearly and concisely with investors and consumers alike. They will develop a strong and lasting presence for the Company’s brands. MCOA will take full advantage of H&D’s ability to reach audiences across a variety of demographics related to our industry and expand our reach into new territory.

“We are very happy to finally be launching our new corporate website. David Hill and the Hill & DraKoln group did a wonderful job on the new site and we look forward to them launching the comprehensive branding and marketing strategy they are developing for the Company,” said Mr. Steinberg, MCOA President & CEO.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Contact:
Marijuana Company of America, Inc
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Tetra Bio-Pharma Strengthens Management Team $TBP.ca

Posted by AGORACOM-JC at 4:34 PM on Wednesday, May 10th, 2017

Tbp large

  • Appointment of Robert Bechard to the position of Vice President, Finance and Business Development
  • Brings more than 20 years’ experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry

OTTAWA, ONTARIO–(May 10, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective today, May 10, 2017.

Mr. Bechard brings more than 20 years’ experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry. As Vice President of Finance and Business Development, Mr. Bechard will be responsible for leading the charge on business development as it relates to the pharmaceutical side of the business and managing the financial side of the company.

During his tenure at RBC Lifesciences Funds I&II, Mr. Bechard was a member of the Senior Management team that delivered top quartile returns in two separate funds. RBC Lifesciences. During his 12-year term as a venture capitalist Mr. Bechard, made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies. As a Board member he played an active role in the negotiation of numerous exits and was also actively involved in taking several companies public in Canada and the U.S. In his two operating roles, he was instrumental in contributing to the growth of two companies actively involved in developing pharmaceuticals. As a consultant to the biopharmaceutical industry Mr. Bechard provided start-up companies with assistance in the areas of fundraising, business development and corporate development.

“We are most pleased to welcome Bob to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Mr. Bechard has built great relations over his career in the pharmaceutical industry which will open new opportunities to further expand our product pipeline through partnerships as we build Tetra into a global leader in pharmaceutical cannabis.”

About Tetra Bio Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(343) 689-0714
edward@tetrabiopharma.com

The marijuana market could be (and possibly already is) bigger than the market for beer in Canada $TBP.ca $N.ca

Posted by AGORACOM-JC at 5:20 PM on Thursday, April 13th, 2017

The marijuana market could be (and possibly already is) bigger than the market for beer in Canada

Pot’s retail therapy

TORONTO — It’s a hot, sunny Thursday afternoon on the hard edge of Queen Street West, and the foot traffic at Eden, a pot dispensary, is brisk.

Retailers along this strip of trendy clothing stores, bars, restaurants, shoe shops, tattoo parlours, hairstylists, comic stores and coffee joints cater to the urban hip, and Eden is no different. lnside, iceberg-blue lights illuminate jewel-case cabinets with the product — glass vials of Hindu Kush, El Hefe, Organic Blue Dream — artfully displayed.

On the aquamarine-blue wall at the front are two white iPads, for customers who need quick access to the Internet to check product information.

The place is spotless, sharp. And the air is heavy with the unmistakeable sweet smell of cannabis.

Pot store
The fridge at Eden Medicinal Society, a cannabis retailer in Toronto. (Tyler Anderson / National Post)

Behind the counter, two clerks, a man and a woman both in their 20s, both dressed like their customers, are filling orders, taking cash.

The average transaction, those in the business say, is $50. A pre-rolled joint is $12, but Alicia, the manager, says they won’t start selling a lot of those until the evening, when the university crowd and the kids from the suburbs come downtown.

The afternoonwalk-ins are largely cannabis users who rely on the flowers, ointments, teas, and oils to ease some chronic ailment, or they are creative types — writers, graphics artists, filmmakers — who find extra insight and energy through cannabinoid stimulation. They all have prescriptions from a licensed physician.

The product mix and retail approach at Eden’s downtown store is different than what you will find at the company’s newest outlet a few blocks north near Bayview and Eglinton. There are more seniors and aging baby boomers in that neighbourhood so the store opens earlier and closes earlier.

The Eden outlets are among the 100 or so pot dispensaries in Toronto, but there is easily demand, those in the industry say, for 1,000 such businesses.

They are owned and operated by a mix of campaigners and capitalists.


The campaigners have been working for years to legalize marijuana use. They believe in the huge potential for the drug to manage pain, ease anxiety, and help many to a more productive, happy, creative and healthy existence.

Tania Cyalume and Brandy Zurborg opened their storefront dispensary, Queens of Cannabis, on Bloor Street West just north of Little Italy in February.

Queens of Cannabis owners Tania Cyalume and Brandy Zurborg outside their shop in May 2016. (Maryam Shah / Postmedia Network)

“I guess when you believe in a product, you really believe in it because you’ve seen the way that it affects people,” said Cyalume.

The products Cyalume and Zurborg sell and their approach to retailing match their personal philosophies and lifestyles. Both are vegans, and the edible cannabis products they stock are vegan and  pesticide-free.

Their crusade is about serving patients because they are patients themselves, and use cannabis products regularly to treat their own chronic pain and ailments.

“We’re patients and we believe in it. We also believe that patients have the first right to access before recreational. There is only so much supply, and there is a huge demand,” said Zurborg, who trained as a certified management accountant designation and was  an auditor with the Canada Revenue Agency.

Their goal is not necessarily to get rich. They speak of one day being able to use the proceeds of their retail operation to help fund outreach, at hospices for example, where they can spread the word about the life-changing value of cannabis products.

Marina, who preferred her last name not be used, is a capitalist. She and her husband have had as many as seven dispensaries, some through a franchise model they were trying to build. When she got into the business a few years ago, she approached with a capitalist’s zeal and eye for profit.

The woman has agreed to talk about her industry at an upscale diner set among the forest of steel-and-glass condominium towers where Lake Ontario meets the Toronto suburb of Etobicoke. She arrived in a gleaming white SUV. Petite, direct and energetic, Marina makes no bones about the fact she got into the business to make a pile of cash.

– See more at: http://news.nationalpost.com/features/o-cannabis-retail-therapy#sthash.q9qC3FZy.dpuf

Tetra Bio-Pharma Announces Opening of a New Brunswick Office for Manufacturing & Sales Activities $TBP.ca

Posted by AGORACOM-JC at 4:46 PM on Wednesday, April 12th, 2017

Tbp large

  • Announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities
  • New Brunswick becoming the hub for the Canadian Cannabis industry

OTTAWA, ONTARIO–(April 12, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities. New Brunswick is becoming the hub for the Canadian Cannabis industry.

Tetra is preparing to commercialize several retail products later this year with expected revenues to be generated for the corporation in the fourth quarter. Tetra has already initiated the process to manufacture the first products that act on the cannabinoid system that will be commercialized later this year for sale in Canada and the USA. The Company also intends on commercializing devices (e.g., pipes) for the consumption of medical marijuana in 2017. The Tetra office in Moncton will be responsible to oversee the timely production and launch of the products as well as adhering to the corporation’s budgets.

Tetra has initiated its Phase I clinical trial in March 2017 after manufacturing the PPP001 cannabis drug product at the Ford Pharma contract manufacturing facility in Moncton, New Brunswick. This contract facility developed the proprietary process and equipment required to produce PPP001 pellets and packaging operations. Tetra is also using the contract services of RPC, a New Brunswick provincial crown corporation, to perform its quality control studies to assure that PPP001 conforms to its drug product specifications and quality requirements of a prescription drug.

“We are pleased to announce the opening of a new office in New Brunswick which has become one of the leading provinces in Canada to support the cannabis industry,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will manufacture our PPP001 prescription drug as well as additional scheduled products later this year. We are advancing our projects forward which are on time and on budget, a key priority for the Tetra team. We are now one-step closer towards our goal of commercialization in bringing our innovative cannabis based products to market.”

“We acted quickly to prepare for the development of this industry in New Brunswick,” said Stephen Lund, CEO of Opportunities NB. “The addition of Tetra Bio-Pharma to the province is welcomed news. We have the research, education and production facilities in place for companies to be successful in this rapidly growing industry.”

According to Dr. Guy Chamberland, CSO at Tetra Bio-Pharma Inc., “The use of the facility in Moncton allows Tetra to manufacture the PPP001 drug product for the clinical trial according to the corporation’s timelines and budget. The RPC research and technology organization provides Tetra with the high-level expertise required for assessing the quality aspects of PPP001 while keeping the costs associated with these activities within budget due to RPC not-for-profit status. I can report that the Phase 1 trial is advancing on schedule and according to the corporation’s plans we expect to complete the Phase Ia portion of the study by mid-May. The results of the Phase Ia will provide TBP with a strategic understanding of the commercial potential of marijuana products and allow the corporation to complete its Phase II and III trial plans.”

About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQX:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714

MCOA Finalizes Joint Venture Agreement With Bougainville Ventures in Washington State $MCOA.us

Posted by AGORACOM-JC at 1:16 PM on Tuesday, April 4th, 2017

15233 mcoa

  • Finalized the joint venture agreement with Bougainville Ventures, Inc. in Washington State
  • MCOA will invest $1 million in cash in a newly formed entity
  • Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility

BONSALL, CA–(Apr 4, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has finalized the joint venture agreement with Bougainville Ventures, Inc. (“BV”) in Washington State.

MCOA will invest $1 million in cash in a newly formed entity. Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility, which will accommodate a Tier-3 production and processing I-502 tenant that has decades of experience and a proven track record of consistency and quality. MCOA and BV will split equity and profits equally, 50/50.

As turnkey landlords, MCOA and BV will provide our I-502 tenant with a state-of-the-art facility that creates an ideal cultivation environment that they can move into and be fully operational on day one. This enables our tenants to focus on what they do best, producing top quality products and not worrying about maintaining their infrastructure.

Donald Steinberg, MCOA President and CEO, said, “This project will help to expand our operations as an ancillary business into the Washington State market. Achieving this milestone of closing this deal, as well as completing our PCAOB audit at the end of the first quarter are two more pillars of the strong foundation we are building for our shareholders.”

The execution of the agreement is the final step in formalizing the Letter of Intent that was publicly announced on February 15, 2017. This joint venture partnership is formed for the purpose of greenhouse construction, management and commercial leasing to I-502 licensed producers within Washington State only and not beyond its borders.

ABOUT BOUGAINILLE VENTURES, INC.

Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on high-density and high-yielding crops. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to tenant-growers and provides growing infrastructure, as well as landlord services for licensed I-502 producers and processors in the state of Washington.

SAFE HARBOR STATEMENT

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Marijuana industry gets boost from anticipated legalization target date $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 9:55 AM on Tuesday, March 28th, 2017

Canadian marijuana businesses got a confidence boost from a CBC News report that the government plans to legalize recreational marijuana by July 2018, although big questions remain about how the legal market will work in different provinces.

The newly revealed date for the debut of legal cannabis is “exactly along the lines of what we expected,” said Neil Maruoka, a stock analyst with Canaccord Genuity who covers publicly traded marijuana companies.

“Certainly there are some companies with more aggressive expansion plans, and this will give some comfort and clarity on what that path forward is going to be,” he said.

Stocks in Canadian marijuana companies swelled on Monday. Shares of Canopy Growth Corp., Canada’s largest publicly traded marijuana producer, gained more than 11 per cent. Shares of Aphria, another large player, gained about 8.4 per cent.

The tabling of the legislation, expected the week of April 10, should be “the tide that lifts all cannabis stocks,” said Maruoka.

Licensed producers bet on recreational sales

Currently, 39 marijuana producers are licensed by Health Canada to cultivate medical marijuana and sell it to patients via a mail-order system. Some of those companies are spending heavily to build up their growing capacity, betting that they’ll be well positioned to sell into the recreational market as soon as the green flag waves.

Alberta-based Aurora Cannabis, which is building an 800,000 square-foot farm near Edmonton International Airport, welcomed the reassurance that Ottawa is committed to recreational sales.

“This is something that we planned on and that’s why we started construction on this enormous facility,” Aurora executive vice-president Cam Battley told CBC Edmonton on Monday.

Canopy Growth CEO Bruce Linton also said the legalization date is in line with his company’s plans.

“It means everything that’s been predicted to be on a path is on a path,” said Linton.

“And when you’re dealing with a government, you can expect things not to stay that course, but they have.”

Who will be allowed to sell?

Even if they weren’t surprised by the date, players in the Canadian marijuana market are taking notice of the news that individual provinces will be deciding how marijuana is sold.

“The dispensary groups, depending on how this plays out, could be big winners,” said Mark Lustig, CEO of CannaRoyalty Corp., which invests in legal aspects of the marijuana industry.

Pharmacies like Shoppers Drug Mart, London Drugs, and Jean Coutu could also benefit if provincial governments tap them as marijuana distributors, said Lustig.

CANADA MARIJUANA/REGULATIONS

Marijuana dispensaries, currently illegal under federal law, could benefit if individual provinces let them sell legal marijuana. (Julie Gordon/Reuters)

In Ontario, the union that represents Liquor Control Board of Ontario workers has pushed for marijuana sales through the government liquor monopoly.

Ontario Premier Kathleen Wynne said Monday that the provincial government has not yet decided who will get to sell marijuana in Canada’s most populous province, although she previously said “it makes sense” to sell marijuana through the LCBO.

Colette Rivet of the Cannabis Canada Association, which represents 15 licensed producers, says her organization’s members favour leaving the mail-order system for medical marijuana in place, and potentially expanding it to recreational sales.

Still, Rivet acknowledges that brick-and-mortar retail sales are “likely to happen, of course.”

In its submission to the federal task force on marijuana legalization, Cannabis Canada said it was against selling alcohol and marijuana in the same location.

Dispensaries hope for inclusion

Owners of some marijuana dispensaries, which are illegal under federal law, are also hoping the provinces will cut them in on the legal marijuana market.

“We feel that we have a very good potential to be included in a regulated environment,” said Jeremy Jacob, a Vancouver dispensary owner and president of the Canadian Association of Medical Cannabis Dispensaries.

In many Canadian cities, dispensaries are frequently raided and shut down by police. But Jacob points out that some B.C. dispensaries have good relationships with local governments in Vancouver and Victoria, where marijuana shops can be licensed by municipal authorities.

Jacob expressed hope that those existing government ties could help pave the way for dispensaries — and the unlicensed producers who grow their product — to take part in the legal marijuana economy in B.C.

“We’re waiting to see how inclusive they actually are,” said Jacob.

Source: http://www.cbc.ca/news/business/marijuana-businesses-legalization-date-1.4042599

Namaste Enters Into Non-Binding LOI With CannMart, a Late Stage ACMPR Applicant $N.ca

Posted by AGORACOM-JC at 9:51 AM on Tuesday, March 21st, 2017

Nlogo

  • Entered into a non-binding letter of intent with Cannmart Inc.
  • Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations
  • CannMart submitted its application to become a “sales only” licensed producer of medical cannabis

VANCOUVER, BRITISH COLUMBIA–(March 21, 2017) –

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 

Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ)(OTCQB:NXTTF) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI“) with Cannmart Inc. (“CannMart“) whereby Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“) (the “Contemplated Transaction“). In 2014, CannMart submitted its application to become a “sales only” licensed producer of medical cannabis (the “ACMPR Application“).

The Contemplated Transaction represents a significant strategic maneuver by Namaste in advance of the potential legalization and regulation of cannabis in Canada. The strategic rationale for the Contemplated Transaction includes:

  • Represents a logical expansion of the product portfolio and generates additional recurring revenue streams from existing and new customers throughout Canada. Creates a one-stop shopping platform for Canadian cannabis consumers;
  • Aligns with Namaste’s e-commerce capabilities and dataset of over 50,000 individuals in Canada, which represents a significant competitive advantage in terms of becoming one of the leading online retailers of cannabis;
  • Complements Namaste’s distribution expertise and relationships with the location of CannMart’s proposed facility enabling same day delivery in the Greater Toronto Area and 24-hour delivery within Canada. Namaste will seek to be the leading online retailer of cannabis in terms of fulfillment and customer service; and
  • Enhances the overall financial profile of the Company in terms of additional revenue and margin generation potential. Attractive non-cash purchase price based on comparable public companies within the industry.

CannMart’s ACMPR Application

CannMart’s ACMPR Application and proposed business model are unique in the industry as CannMart has applied only to sell and not produce medical cannabis. Under this model and subject to obtaining a licence from Health Canada, CannMart would have the ability to purchase wholesale medical cannabis from other licensed producers and sell to individual patients in accordance with the ACMPR.

The ACMPR Application has completed the “security clearance” stage and is currently in the “review” stage of the licensing process. CannMart’s proposed facility is a 4,000 sq. ft. industrial building located in Etobicoke, Ontario (the “Facility“). Pursuant to the LOI, the Company will assume all of the going forward liabilities and obligations of CannMart, including the remaining build-out costs needed to prepare the Facility for the final stages of the licensing process and the pre-licensing inspection.

Terms of the Contemplated Transaction

Upon execution of the LOI, Namaste paid $50,000 (the “Initial Payment“) in cash to CannMart’s counsel, to be held in trust and released upon closing of the Contemplated Transaction. If Namaste does not provide CannMart with notice of completion of its due diligence within 30 days of the execution of the LOI, the Initial Payment will become non-refundable. The parties anticipate signing a definitive agreement in mid-late April.

Consideration for the Contemplated Transaction will be satisfied with common shares in the capital of the Company. A portion of common shares of the Company will be issued on closing of the Contemplated Transaction, and the remaining common shares of the Company will be issued upon the occurrence of certain milestones. The share price shall be the five-day trailing volume weighted average price prior to the day on which the Company announces the Contemplated Transaction, subject to compliance with all stock exchange and regulatory requirements.

Clarus Securities Inc. is acting as financial advisor to Namaste in connection with the Contemplated Transaction.

Conditions to Closing

Closing of the Contemplated Transaction is subject to the following:

  • Completion of a definitive share purchase agreement containing representations, warranties and covenants customary in a transaction of this nature;
  • Completion of all financial and legal due diligence;
  • Execution of an employment or consulting agreement with each of CannMart’s existing team members for the purposes of the MMPR Application or longer;
  • Receipt of all director and shareholder approvals, if necessary, and requisite regulatory approvals of each party relating to the Contemplated Transaction;
  • Each of the current directors and officers of CannMart (other than as agreed to by Namaste) having delivered resignations and releases to CannMart; and
  • Such other documentation and closing conditions as are customary for transactions similar to the Contemplated Transaction.

Management Commentary

Mr. Sean Dollinger, President and CEO of Namaste, comments: “The acquisition of CannMart represents a significant strategic transaction for Namaste. One of the core competitive advantages of Namaste is the international customer list we have built, which enables us to enter markets with new product offerings and instantly generate revenues. The addition of consumables to our product offering in Canada is an excellent example of this competitive advantage and we see multiple opportunities to obtain additional licences in international jurisdictions where we have a strong customer foothold.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger

Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com

Namaste Announces MOU With Vinergy $N.ca

Posted by AGORACOM-JC at 8:22 AM on Tuesday, March 14th, 2017

Nlogo

  • Entered a memorandum of understanding with Vinergy Resources Ltd., to jointly market Vinergy’s proprietary Cannabidiol (CBD) extract formulations through referral traffic generated on Namaste’s sales channels and websites
  • CEO of Namaste, comments: “We are very pleased to work with Vinergy to further expand our product line. This relationship represents continued monetization of Namaste’s database and we view broadening our strategic alliances to the benefit of our customers and shareholders”.

VANCOUVER, BRITISH COLUMBIA–(March 14, 2017) –Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(OTCQB:NXTTF)(FRANKFURT:M5BQ) is pleased to announce that it has entered a memorandum of understanding (“MOU“) with Vinergy Resources Ltd. (“Vinergy“), to jointly market Vinergy’s proprietary Cannabidiol (CBD) extract formulations through referral traffic generated on Namaste’s sales channels and websites.

In the first phase of the collaboration, through channels in California, Colorado and potentially other legal States, Namaste will market Vinergy’s proprietary formulations to consumers in its database of 300,000 customers.

Management Commentary 

Mr. Sean Dollinger, President and CEO of Namaste, comments: “We are very pleased to work with Vinergy to further expand our product line. This relationship represents continued monetization of Namaste’s database and we view broadening our strategic alliances to the benefit of our customers and shareholders”.

About Namaste Technologies Inc. 

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com
www.namastetechnologies.com